Mayo Comprehensive Cancer Center Grant

梅奥诊所癌症中心(MCCC)是梅奥诊所/梅奥医学院的一个矩阵中心。该中心由来自3个地理地点(明尼苏达州罗切斯特、佛罗里达州杰克逊维尔和亚利桑那州凤凰城/斯科茨代尔)的55个部门的428名成员(自2003年以来净增97名新成员)组成。MCCC的目标是今天提供最好的癌症护理，同时为未来制定改进的战略，为美国和世界各地的癌症患者提供服务。MCCC有12个研究项目：女性癌症、胃肠癌、前列腺癌、恶性血液病、神经肿瘤学、癌症成像、细胞生物学、发展治疗学、免疫学和免疫疗法、基因和病毒疗法、遗传流行病学和风险评估、癌症预防和控制。研究由15个共享资源推动：调查研究、药剂学、生物统计学、生物信息学、组织和细胞分子分析、生物样品加入和加工、临床研究办公室；转基因和基因靶向小鼠共享资源、蛋白质化学和蛋白质组学、流式细胞术/光学形态学、电子显微镜、药理学、基因和病毒疗法、细胞遗传学和基因分析。自上次续签以来，MCCC继续增长，同行审查资金总额从7,760万美元增加到1.058亿美元，NCI资金从5,630万美元增加到7,570万美元。特别值得注意的是，除了研究人员发起的赠款增加外，MCCC还增加了2个新的孢子(乳房和大脑)和2个新的培训赠款。此外，还成功地更新了4个其他孢子(淋巴瘤、前列腺癌、多发性骨髓瘤、胰腺)，以及几个多学科(P01、N01、2个U01和2个U10)和4个培训补助金。在此期间，年度出版物增长了28%，特别是影响较大的临床和科学出版物，这证明了研究效率。自上次竞争性续签以来，MCCC受益于：1)新设施，新实验室面积(&gt；10万平方英尺)以及新的住院/门诊空间；2)机构承诺增加，a)11个新的捐赠教授职位(2200万美元机构/2200万美元慈善事业)，b)15名新教师的工资/启动资金，c)加强MCCC在3个地点的整合(760万美元)，以及d)资金，以提高在MCA和MCF临床试验中未得到充分服务的少数族裔的收益(5年内1300万美元)。在过去的5年里，CCSG的发展基金一直被用来帮助这3个地点的教师招聘。在接下来的5年里，我们计划扩大遗传学、肺癌和黑色素瘤的研究。

The Mayo Clinic Cancer Center (MCCC) is a matrix center within the Mayo Clinic / Mayo Medical School. The Center is made up of 428 members (net increase of 97 new members since 2003) from 55 departments based at 3 geographical sites (Rochester, MN - MCR; Jacksonville, FL - MCF; and Phoenix/Scottsdale, AZ - MCA). The goal of the MCCC is to provide the best cancer care today, while developing improved strategies for tomorrow, serving cancer patients throughout the U.S. and the world. MCCC has 12 research programs: Women's Cancer; Gastrointestinal Cancer; Prostate Cancer; Hematologic Malignancies; Neuro-oncology; Cancer Imaging; Cell Biology; Developmental Therapeutics; Immunology & Immunotherapy; Gene & Virus Therapy; Genetic Epidemiology & Risk Assessment; Cancer Prevention & Control. Research is facilitated by 15 shared resources: Survey Research, Pharmacy, Biostatistics, Bioinformatics, Tissue & Cell Molecular Analysis, Biospecimens Accessioning & Processing, Clinical Research Office; Transgenic & Gene Targeted Mouse Shared Resource, Protein Chemistry & Proteomics, Flow Cytometry/Optical Morphology, Electron Microscopy, Pharmacology, Gene & Virus Therapy, Cytogenetics, and Gene Analysis. Since the last renewal, MCCC has continued to grow with an increase in overall peer-reviewed funding from $77.6 million to $105.8 million and an increase in NCI funding from $56.3 million to $75.7 million. Of particular note is that, in addition to an increase in investigator-initiated grants, MCCC has 2 new SPOREs (Breast and Brain) and 2 new training grants. Furthermore, there has been successful competitive renewal of 4 other SPOREs (Lymphoma, Prostate, Multiple Myeloma, Pancreas), as well as several multidisciplinary (P01, N01, 2 U01s, and 2 U10s) and 4 training grants. Research productivity is demonstrated by a 28% increase in annual publications during this period, particularly high impact clinical and scientific publications. Since the last competitive renewal, MCCC has benefited from: 1) new facilities with a net increase in new lab space (>100,000 sq ft) as well as new inpatient / outpatient space; 2) increased institutional commitment with a) 11 new endowed professorships ($22M institutional / $22M philanthropic), b) salary/start-up funds for 15 new faculty, c) funds to enhance integration of MCCC across 3 sites ($7.6M), and d) funds to enhance accrual of underserved minorities to clinical trials at MCA and MCF ($13M over 5 years). During the past 5 years, Developmental Funds from CCSG have been leveraged to aid in faculty recruitment at each of the 3 sites. During the next 5 years, we have plans to expand genetics, lung cancer, and melanoma research.